Teva to pay $450 million to resolve US kickback, price-fixing cases
Adds details on settlement, background of case throughout
By Nate Raymond
BOSTON, Oct 10 (Reuters) -Teva Pharmaceutical Industries Ltd TEVA.TA has agreed to pay $450 million to resolve allegations it used charities that help cover Medicare patients' out-of-pocket drug costs as a means to pay kickbacks to boost sales of its multiple sclerosis drug Copaxone and conspired to fix prices for generic drugs.
The two settlements announced by the U.S. Department of Justice on Thursday included one for $425 million resolving a lawsuit filed in federal court in Boston in 2020 as part of an industry-wide probe of drugmakers' financial support of patient assistance charities.
That investigation had previously resulted in more than $1 billion in settlements with 12 drugmakers, four charities and one pharmacy. A lawsuit against Regeneron Pharmaceuticals arising from the same probe remains pending.
Israel-based Teva earliersaid in court papers that it faced triple damages under the False Claims Act of as much as $10 billion in the Justice Department's lawsuit.
The Justice Department also announced a separate $25 million civil settlement with Teva resolving claims that itconspired to fix prices and allocate markets for two generic drugs. It last year agreed to pay $225 million to resolve a related criminal case.
Teva in a statement said the $450 million would be paid over six years. Teva said it did not admit wrongdoing in either settlement and continues to maintain that its donations to charities "supported MS patients’ access to critical medicines."
Drug companies are prohibited from subsidizing co-payments for patients enrolled in Medicare, the government healthcare program for those aged 65 and older. Companies may donate to non-profits providing co-pay assistance as long as they are independent.
But the government has alleged that various pharmaceutical companies used such charities as a means to improperly coverthe co-pay obligations of Medicare patients using their drugs, in violation of the Anti-Kickback Statute.
The lawsuit in Boston alleged Teva paid two such charitable foundations, the Chronic Disease Fund and The Assistance Fund, more than $350 million from 2006 to 2017 to cover co-payments for Copaxone patients, turning the charities into vehicles to pay kickbacks to patients to use the drug.
During that time, Teva quintupled the drug's price to about $85,000 per year from approximately $17,000. The drug at that time was Teva's best seller, generating $3.8 billion in revenues in 2017 alone.
Reporting by Jasper Ward and Katharine Jackson; editing by David Ljunggren and Leslie Adler
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
